ATE478893T1 - Genetisch hergestellte zellen für therapeutische anwendungen - Google Patents

Genetisch hergestellte zellen für therapeutische anwendungen

Info

Publication number
ATE478893T1
ATE478893T1 AT05763600T AT05763600T ATE478893T1 AT E478893 T1 ATE478893 T1 AT E478893T1 AT 05763600 T AT05763600 T AT 05763600T AT 05763600 T AT05763600 T AT 05763600T AT E478893 T1 ATE478893 T1 AT E478893T1
Authority
AT
Austria
Prior art keywords
therapeutic applications
genetically designed
designed cells
cells
genetically
Prior art date
Application number
AT05763600T
Other languages
English (en)
Inventor
Marc Penn
Matthew Kiedrowski
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Application granted granted Critical
Publication of ATE478893T1 publication Critical patent/ATE478893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
AT05763600T 2004-05-19 2005-05-17 Genetisch hergestellte zellen für therapeutische anwendungen ATE478893T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57234904P 2004-05-19 2004-05-19
PCT/US2005/017050 WO2005116192A2 (en) 2004-05-19 2005-05-17 Genetically engineered cells for therapeutic applications

Publications (1)

Publication Number Publication Date
ATE478893T1 true ATE478893T1 (de) 2010-09-15

Family

ID=35451463

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05763600T ATE478893T1 (de) 2004-05-19 2005-05-17 Genetisch hergestellte zellen für therapeutische anwendungen

Country Status (9)

Country Link
US (3) US20050271639A1 (de)
EP (1) EP1763538B1 (de)
JP (1) JP5095403B2 (de)
CN (1) CN101065400A (de)
AT (1) ATE478893T1 (de)
AU (1) AU2005248352B2 (de)
CA (1) CA2567177C (de)
DE (1) DE602005023158D1 (de)
WO (1) WO2005116192A2 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP2008514188A (ja) * 2004-09-24 2008-05-08 アンジオブラスト システムズ，インコーポレーテッド 間葉系前駆細胞（ｍｐｃ）の増殖および／または生存を増強させる方法
GB0514300D0 (en) * 2005-07-12 2005-08-17 Fond Ct San Raffaele Imflammation
US8168169B2 (en) * 2006-08-09 2012-05-01 Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
US7696309B2 (en) * 2006-10-23 2010-04-13 The Brigham And Women's Hospital, Inc. Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
CA2682469A1 (en) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
US8440199B2 (en) * 2007-12-12 2013-05-14 Imperial Innovations Limited Methods for mobilizing mesenchymal stem cells in a patient
CA2709398C (en) * 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
WO2009134532A2 (en) * 2008-03-07 2009-11-05 The Trustees Of Columbia University In The City Of New York Homing in mesenchymal stem cells
WO2010111522A2 (en) 2009-03-26 2010-09-30 The Regents Of The University Of California Mesenchymal stem cells producing inhibitory rna for disease modification
US20100247495A1 (en) * 2009-03-30 2010-09-30 Tom Ichim Treatment of Muscular Dystrophy
AU2010286511B2 (en) 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue
WO2011047058A2 (en) * 2009-10-13 2011-04-21 Allocure Inc. Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
EP2625264B1 (de) 2010-10-08 2022-12-07 Terumo BCT, Inc. Verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem mit steuerungsbedingungen
US10662234B2 (en) 2011-06-07 2020-05-26 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
EP2626369A1 (de) * 2011-11-24 2013-08-14 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Gentechnisch veränderte mesenchymale Stammzellen und ihre therapeutische Verwendung
HUE041853T2 (hu) * 2012-05-21 2019-05-28 Univ California Humán IPS sejtek elõállítása szintetikus önreplikációra képes RNS segítségével
US20140065110A1 (en) 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
WO2014145199A2 (en) * 2013-03-15 2014-09-18 The Cleveland Clinic Foundation Retrograde delivery of sdf-1 for treatment of myocardial infarction
JP6612227B2 (ja) 2013-11-16 2019-11-27 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
CN106029086A (zh) * 2013-12-13 2016-10-12 美索布拉斯特国际有限公司 使用基质细胞来源的因子-1的抗蛋白酶突变体修复组织损伤的方法
EP3613841B1 (de) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passives ersetzen von medien
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN111742044A (zh) 2017-10-03 2020-10-02 沃尔基尔生物制药公司 用遗传修饰的β细胞治疗糖尿病
WO2019204509A2 (en) * 2018-04-18 2019-10-24 Summa Health Compositions and methods for the treatment of ischemia and cardiomyopathy
WO2020023806A1 (en) * 2018-07-25 2020-01-30 The Johns Hopkins University Compositions and methods for generation of heart field-specific progenitor cells

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
EP0557459B1 (de) 1990-11-13 1997-10-22 Immunex Corporation Bifunktionelle wählbare fusionsgene
US5197985A (en) 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
EP0804590A1 (de) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunktionelle selektierbare fusionsgene auf dem cytosin-deaminase (cd) gen beruhend
US5602301A (en) * 1993-11-16 1997-02-11 Indiana University Foundation Non-human mammal having a graft and methods of delivering protein to myocardial tissue
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
CA2188575A1 (en) * 1995-02-28 1996-09-06 H. Kirk Hammond Gene transfer-mediated angiogenesis therapy
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US7393528B2 (en) * 1997-01-09 2008-07-01 Tvedten Stephen L Biological pesticide
US6121428A (en) * 1997-06-13 2000-09-19 Genentech, Inc. Protein recovery
AU8401498A (en) * 1997-07-14 1999-02-10 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
EP1053326A2 (de) * 1998-02-06 2000-11-22 Collateral Therapeutics Varianten des angiogenen faktors vaskularer endothelialzell-wachstumsfaktor: vegf
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20020107196A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
IL125532A0 (en) * 1998-07-27 1999-03-12 Yeda Res & Dev Hematopoietic cell composition for use in transplantation
AU5241099A (en) * 1998-07-31 2000-02-21 Trustees Of Columbia University In The City Of New York, The Use of inhibitors of the activation of cxcr4 receptor by sdf-1 in treating rheumatoid arthritis
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
CA2367173A1 (en) * 1999-04-08 2000-10-12 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
US7125856B1 (en) * 1999-04-15 2006-10-24 St. Elizabeth's Medical Center Of Boston, Inc. Angiogenic growth factors for treatment of peripheral neuropathy
US6358697B2 (en) * 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
MXPA02012067A (es) * 2000-06-05 2004-08-19 Univ Columbia Identificacion y uso de celulas endoteliales precursoras derivadas de medula osea par mejorar la funcion del miocardio despues de dano isquemico.
AU2001284695A1 (en) * 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7402567B2 (en) * 2000-10-27 2008-07-22 The Regents Of The University Of California Treatment of disease by inducing cell apoptosis
WO2002036078A2 (en) * 2000-11-05 2002-05-10 University Of Florida Targeting pluripotent stem cells to tissues
AU2002224851A1 (en) * 2000-11-14 2002-05-27 Universite Libre De Bruxelles Generation and use of dendritic cells
US20020111290A1 (en) * 2000-12-01 2002-08-15 Bernhard Homey Uses of mammalian genes and related reagents
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
EP1424389A4 (de) * 2001-08-07 2004-08-25 Kirin Brewery Verfahren zur herstellung hämatopoetischer stammzellen
JP4906231B2 (ja) * 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
US7402724B2 (en) * 2002-01-04 2008-07-22 Mayo Foundation For Medical Education And Research Longevity and PAPP-A
JPWO2003059375A1 (ja) * 2002-01-17 2005-05-19 株式会社カルディオ 組織再生複合療法
US7396537B1 (en) * 2002-02-28 2008-07-08 The Trustees Of The University Of Pennsylvania Cell delivery patch for myocardial tissue engineering
KR20050013531A (ko) * 2002-03-15 2005-02-04 디파트먼트 오브 베테랑스 어페어스 오피스 오브 더 제네럴 카운셀 (024) 세포의 아시알로결정자 및 당접합체를 이용하여 세포를조직 및 기관으로 표적화하는 방법 및 이를 위한 조성물
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP2004099471A (ja) * 2002-09-05 2004-04-02 Cardio Corp 心筋梗塞および心不全の治療薬
WO2004044142A2 (en) * 2002-11-05 2004-05-27 The Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
JP4672370B2 (ja) * 2002-12-05 2011-04-20 ケース ウエスタン リザーブ ユニバーシティ 虚血の細胞ベースの治療
AU2003902037A0 (en) * 2003-04-24 2003-05-15 Mclachlan, Craig Method for tissue growth
US7396680B2 (en) * 2003-10-31 2008-07-08 Cornell Research Foundation, Inc. Stem cell-specific promoters and their use
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US20060105950A1 (en) * 2004-10-25 2006-05-18 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Morphogen compositions and use thereof to treat wounds
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20070173471A1 (en) * 2006-01-24 2007-07-26 Losordo Douglas W Morphogen compositions and methods of use thereof to treat heart disorders
US7405195B2 (en) * 2006-03-27 2008-07-29 Natural Beauty Bio-Technology Limited Cosmetic compositions
CA2682469A1 (en) * 2007-03-30 2008-10-09 The Cleveland Clinic Foundation Method of treating ischemic disorders
CA2709398C (en) * 2007-12-14 2017-11-07 The Cleveland Clinic Foundation Use of stromal cell-derived factor 1 for promoting wound healing
AU2010286511B2 (en) * 2009-08-28 2016-05-26 Juventas Therapeutics, Inc. SDF-1 delivery for treating ischemic tissue

Also Published As

Publication number Publication date
CN101065400A (zh) 2007-10-31
AU2005248352A1 (en) 2005-12-08
WO2005116192A2 (en) 2005-12-08
US20070224171A1 (en) 2007-09-27
US20050271639A1 (en) 2005-12-08
US20070258943A1 (en) 2007-11-08
DE602005023158D1 (de) 2010-10-07
CA2567177A1 (en) 2005-12-08
EP1763538B1 (de) 2010-08-25
AU2005248352B2 (en) 2009-07-30
CA2567177C (en) 2011-08-09
WO2005116192A3 (en) 2006-04-13
JP2007537752A (ja) 2007-12-27
EP1763538A2 (de) 2007-03-21
JP5095403B2 (ja) 2012-12-12

Similar Documents

Publication Publication Date Title
ATE478893T1 (de) Genetisch hergestellte zellen für therapeutische anwendungen
AR105435A2 (es) Método de recombinación homóloga intramolecular en el genoma de una célula vegetal
WO2010141801A3 (en) Reprogramming t cells and hematophietic cells
ATE530638T1 (de) Pluripotente autologe stammzellen aus der mündlichen oder gastrointestinalen schleimhaut
MY159971A (en) Multipotent/pluripotent cells and methods
EA201270187A1 (ru) Ферментативное продуцирование этанола, не содержащего глицерин
ES2570382T3 (es) Composiciones y métodos para la producción de azúcares fermentables
BR112012015576A2 (pt) "cerâmica de vidro de dissilicato de lítio, método para sua fabricação e seu uso"
BR112013002811A8 (pt) meios básicos simplificados para cultura celular pluripotente de humano
BRPI0917993A2 (pt) composições de célula-tronco mesenquimal purificada e métodos de purificação de composições de célula-tronco mesenquimal purificda.
NZ600585A (en) Expression of hexose kinase in recombinant host cells
SG196784A1 (en) Stem cell cultures
IL189555A0 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
BRPI0514343A (pt) combinações de quimiocinas para mobilizar células progenitoras/tronco
EA201492273A1 (ru) Композиции полимера мирцена
ES2571757T3 (es) Microorganismos con rango de utilización de sustrato ampliado
PE20130213A1 (es) Marcadores predictivos utiles en el tratamiento del sindrome fragil x (fxs)
NZ599774A (en) Melanocortin-1 receptor-specific cyclic peptides
ATE536914T1 (de) Spezifische cd4+cd25+-regulatorische t-zellen für die hämatopoetische zelltransplantation und immuntoleranz
CR8680A (es) Derivados de piperazinilpiperidina como antagonistas del receptor de quimiocina
WO2012088225A3 (en) Method for identifcation and culture of multipotent mesenchymal stem cells with high proliferation potential
WO2010059876A3 (en) In vitro human b lymphopoiesis culture system
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
MX2011007936A (es) Metodos para regeneracion de tejido pancreatico.
EP2435558A4 (de) Erzeugung genetisch korrigierter krankheitsfreier induzierter pluripotenter stammzellen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties